Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms, molecular targets, and drug discovery without new human trial data
PubMed 16611081 · doi:10.2174/092986706776361003
What was done
This review evaluates the physiological mechanisms, molecular targets, and drug discovery strategies for bile acid reabsorption inhibitors (BARIs), specifically targeting the ileal bile acid transporter (IBAT/ASBT) to treat hyperlipidemia through gut-restricted compounds.
What was found
The abstract reports no empirical data, trial counts, or quantitative efficacy metrics. It outlines the biochemical mechanism: inhibiting IBAT interrupts the enterohepatic circulation of bile acids, relieving feedback inhibition on hepatic cholesterol-7alpha-hydroxylase, upregulating hepatic LDL receptors, and consequently reducing serum LDL levels through locally acting, minimally absorbed molecules.
Why it matters
It outlines the medicinal chemistry rationale for gut-restricted hypolipidemic agents designed to lower cholesterol without entering systemic circulation, potentially avoiding hepatic metabolism and statin-like drug-drug interactions.
Limits
As a narrative overview, it provides no clinical trial data, comparative efficacy statistics, patient sample sizes, or adverse effect measurements (such as gastrointestinal tolerability). Real-world clinical efficacy and safety cannot be evaluated from this record.
Cited by
- supports Approximately 90 percent of bile is reabsorbed at the end of the small intestine and recycled.